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Objective: To evaluate the monogalactosyl diglyceride (MGDG) and digalactosyl diglyc-
eride (DGDG) from Clinacanthus nutans (C. nutans) for their in vitro antiviral activities
against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) by plaque reduction assay.
Methods: MGDG and DGDG were extracted with chloroform from C. nutans leaves.
MGDG and DGDG were separated from chloroform crude extract using column chroma-
tography, characterized by thin layer chromatography and quantiﬁed by high performance
liquid chromatography. The anti HSV-1 and 2 activity against pre-treatment and post-
treatment of the compounds was evaluated using plaque reduction assay. The cytotox-
icity of the extract and the compounds on Vero cells were performed by MTT assay.
Results: MGDG and DGDG obtained by column chromatography showed identical pro-
ﬁles as standard MGDG and standard DGDG using thin layer chromatography and high
performance liquid chromatography. MGDG and DGDG from C. nutans showed 100%
inhibition of HSV-1 replication at the post step of infection at noncytotoxic concentration
with IC50 values of 36.00 and 40.00 mg/mL, and HSV-2 at 41.00 and 43.20 mg/mL,
respectively.Moreover, MGDG and DGDG fromC. nutanswere demonstrated to have anti-
herpes simplex activity at the same level as standard synthetic compounds. In contrast, pre-
treatment of Vero cells with MGDG and DGDG before HSV-1 and HSV-2 infection did not
show inhibitory effect against these viruses. MGDG and DGDG exhibited antiviral activity
against HSV-1 with selectivity index of 26.00 and 23.00 and HSV-2 of 23.30 and 21.30.
Conclusions: MGDG and DGDG from C. nutans, a traditional Thai herbal medicine
illustrated inhibitory activity against HSV-1 and HSV-2, probably by inhibiting the late
stage of multiplication, suggesting their promising use as anti-HSV agents.1. Introduction
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in-
fections are distributed worldwide in humans with different degree
of severity. It may lead to life-threatening conditions, especially in
immunocompromised patients. HSV-1 is more frequently associ-
ated with orofacial mucocutaneous lesions. HSV-2 is more
commonly associated with genital herpes. Herpes viruses can cause
primary, and recurrent infections upon viral reactivation through
stimuli such as sunlight, stress and weakened immunity [1,2]. Thearticle under the CC BY-NC-ND license (http://
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acyclovir, a nucleoside analog, which selectively inhibits HSV
replication with low host cell toxicity [3,4]. However, the
emergence of resistant viruses to commonly used antiviral drugs is
a problem in the treatment, particularly in immunocompromised
patients and infants [5–7]. Consequently, there is a need to search
for new and more effective antiviral agents that can substitute or
complement currently used antiviral drugs [8].
Medicinal plants are known to be a source of abundant of
chemical compounds and traditionally used in healthcare in many
countries. A large number of plants, either as extracts or as pure
compounds, have been demonstrated to exhibit antiviral activity [9–
11].Clinacanthus nutans (Burm. f.) Lindau (C. nutans) is amedicinal
plant in family Acanthaceae which is native to many tropical Asia
countries including Thailand and often cultivated. C. nutans has
been traditionally used as a medicine for topical treatment of skin
rashes, insect and snake bite, HSV, and varicella-zoster virus le-
sions [12,13]. Clinical trials have reported the successful use of
C. nutans topical treatment for relief of skin inﬂammation and
insect bites, genital herpes and varicella-zoster lesions [14]. Crude
extract of C. nutans leaves was shown to inhibit HSV-1 and HSV-
2 activity [15]. In phytochemical investigation, ﬂavonoids, steroids,
triterpenoids, cerebrosides, two glycoglycerolipids, glycerides,
sulfur-containing glycerides were isolated from this plant [16,17].
Trigalactosyl and digalactosyl diglycerides isolated from C. nutans
have been shown to exhibit antiviral activity [18]. Synthetic
glycoglycerolipids has also been shown to inhibit HSV [19].
In this study, the inhibition of HSV-1 and HSV-2 by two
glycoglycerolipids: monogalactosyl diglyceride (MGDG) and
digalactosyl diglyceride (DGDG), isolated from C. nutans and
chloroform crude extract of C. nutans leaves were investigated
using plaque reduction assay. Furthermore, the mode of the
inhibitory activities was also determined by adding the com-
pound in the different step of virus replication.
2. Materials and methods
2.1. Plant material and extraction
C. nutans plants were collected from Uthai Thani, Thailand
by Warayu Leeprasert, Thai medicinal plant expert. Dried leaves
were extracted with chloroform using a Soxhlet extraction
apparatus at 60 C for 8 h. Whole extracts were collected and the
solvent evaporated to dryness with a rotary evaporator. The
crude extracts were stored at −20 C until used in tests.
2.2. Preparation of MGDG and DGDG
The crude extracts were partially puriﬁed on a column of
silica gel 60 by exhaustive elution with 350 mL of each of the
following elution steps: chloroform: acetone (9:1, 3:1 and 1:1),
pure acetone and acetone: methanol (3:1) [20]. And 50 mL of
each fraction was collected and evaporated for further
identiﬁcation of MGDG and DGDG.
Each fraction was veriﬁed for MGDG and DGDG by thin
layer chromatography (TLC) and compared with standard
MGDG and DGDG (Larodan AB, Sweden). The phase for
MGDG identiﬁcation consisted of chloroform: acetone: distilled
water (30:60:2). Mobile phase for DGDG identiﬁcation
consisted of chloroform: acetone: methanol: glacial acetic acid:
distilled water (100:40:20:30:10) [21].Fractions which contained MGDG or DGDG were pooled and
evaporated using rotary evaporator. Conﬁrmation of MGDG was
performed using TLC with 2 systems of mobile phase, chloro-
form: acetone: distilled water (30:60:2) and acetone: glacial acetic
acid: distilled water (100:2:1) [22]. Conﬁrmation of DGDG was
performed using TLC with 2 systems of mobile phase,
chloroform: methanol: glacial acetic acid: distilled water
(85.0:15.0:10.0:3.5) [22] and chloroform: acetone: methanol:
glacial acetic acid: distilled water (100:40:20:30:10) [21].
The quantity of MGDG and DGDG was observed and
determined by high performance liquid chromatography (HPLC)
using an Agilent 1100 equipped with photo diode array detector
at 254 nm. MGDG and DGDG were separated at 30 C using a
silica column, size 200.0 mm × 4.6 mm, particle size 5 mm
(hypersil silica). The ﬂow rate was 1 mL/min and the mobile
phase was hexane: iso-propanol (97.5:2.5) [23].
2.3. Viruses and cell lines
Vero cells (African green monkey kidney cells) were grown in
monolayer cultured with Dulbecco's modiﬁed Eagle medium,
supplemented with 5% fetal bovine serum. HSV-1 and HSV-2
were provided by Dr. Panadda Dhepakson, Medical Biotech-
nology Center, Department of Medical Science, Thailand. Virus
stocks were prepared from infected cultures in Vero cells with
maintenance medium (Dulbecco's modiﬁed Eagle medium, 2%
fetal bovine serum and 1% antibiotic), propagated at 37 C, 5%
CO2 and virus titer was determined by plaque assay in Vero cells.
2.4. Cytotoxicity assay
Cytotoxicity was evaluated by the MTT assay. A volume of
100 mL of Vero cells at concentration 2.5 × 105 cell/mL were
seeded in 96-well plate and propagated at 37 Cwith 5%CO2 for 1
day. The cultured medium was replaced by fresh maintenance
medium containing different concentrations of chloroform crude
extract, extracted and puriﬁed MGDG or DGDG. The cells were
incubated at 37 C with 5% CO2 for 2 days, and the MTT reagent
(20mL)was added to eachwell. After 4 h of further incubation, the
formazan was solubilized by adding diluted HCl (0.04 mol/L) in
isopropanol, and the absorbance was determined at 490 nm by
Biotek ELISA plate reader with a reference wavelength of
620 nm. The 50% cytotoxic concentration (CC50) causing visible
morphological changes in 50% of Vero cells were determined [24].
2.5. Antiviral activity assay
The antiviral activity of glycoglycerolipid from Phaya Yaw
was evaluated by plaque reduction assay as previously described
[25]. The compounds were added at different stage during viral
infection cycle in order to trace the mode of antiviral action.
2.6. Pre-treatment
The Vero cell monolayer was pretreated with chloroform
crude extract, MGDG, DGDG, standard MGDG, standard
DGDG and acyclovir at 37 C for 24 h prior to virus infection.
After washing, cells were infected with HSV-1 or HSV-2 at a
multiplicity of infection of 0.1 at 37 C for 1 h. The infected
cells were washed, and overlaid with 3 mL of 1.2% nutrient
methylcellulose and incubated at 37 C for 48 and 96 h for HSV-
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5% formaldehyde, stained with 0.5% crystal violet and then the
number of plaques was counted. The percentage of inhibitory
activity concentration was determined and the IC50 was deter-
mined from the curve relating the percentage of inhibitory ac-
tivity concentration to the concentration of the samples.
2.7. Post-treatment
Conﬂuent Vero cells were infected with 100 plaque forming
unit of HSV-1 or HSV-2. After adsorption at 37 C for 1 h, the
infected cells were washed and overlaid with 3 mL of 1.2%
nutrient methylcellulose containing chloroform crude extract,
MGDG, DGDG, standard MGDG, standard DGDG and
acyclovir in various concentration and incubated at 37 C for 48
and 96 h for HSV-1 and HSV-2, respectively. The cells were
then treated as described earlier for the viral plaque number
reduction assay.
3. Results
3.1. Isolation and characterization of crude extract and
MGDG and DGDG from C. nutans
Crude extract of C. nutans dried leaves was obtained after
chloroform extraction with yield of 7%. The crude extract was
then run through a silica gel column and sequentially eluted with
5 different eluants. Fractions of 50 mL were collected as per the
method described by Diehl et al. [20]. After running the crude
extract, MGDG was eluted from fractions 12–15 and DGDG
was eluted from fractions 26–28. The pooled portions of eachM
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Figure 1. TLC chromatogram of extracted and puriﬁed MGDG from C. nuta
glacial acetic acid: water (b), extracted and puriﬁed DGDG from C. nutans and
acetic acid: water (d).fraction of MGDG and DGDG were preliminary identiﬁed by
TLC (Figure 1) when using different mobile phase systems.
The MGDG from C. nutans showed similar Rf as the standard
MGDG (Figure 1a,b) as well as the DGDG from C. nutans and
the standard DGDG (Figure 1c,d). The identiﬁcation of MGDG
and DGDG extracts were conﬁrmed by HPLC. HPLC proﬁles
obtained from MGDG and DGDG extracts were compared well
to that of standard MGDG and DGDG (Figure 2).
3.2. Cytotoxicity
To examine the possible cytotoxic effects of chloroform
extract, extracted and puriﬁedMGDG and DGDG fromC. nutans
on cell viability, Vero cells were incubated with different con-
centrations (100–15000 mg/mL) of the compounds for 48 h and
cell viability was measured byMTT assay. As shown in Figure 3,
extracted and puriﬁedMGDG and DGDG fromC. nutans showed
a lower toxic effect than chloroform crude extract. In Table 1, the
CC50 for these compounds were reported. In this study, chloro-
form extract, extracted and puriﬁed MGDG and DGDG from
C. nutans were investigated for the effectiveness against HSV-1
and HSV-2 infected Vero cells. In Vero cells, the CC50 of chlo-
roform extract, extracted and puriﬁed MGDG and DGDG from
C. nutans was between 520 and 960 mg/mL. Activity of the
extracted and puriﬁedMGDGandDGDG fromC. nutanswas less
toxic than the chloroform crude extract.
3.3. Anti HSV-1 and 2 activity
The effect of chloroform extract, MGDG and DGDG from
C. nutans on HSV was evaluated for inhibition at different stepsD
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Figure 2. HPLC chromatogram.
A: Extracted and puriﬁed MGDG from C. nutans; B: Standard MGDG; C: Extracted and puriﬁed DGDG from C. nutans; D: Standard DGDG.
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extract, extracted and puriﬁed MGDG, extracted and puriﬁed
DGDG, standard MGDG and standard DGDG in different
concentrations at subtoxic levels. For post-treatment, the com-
pounds were added to the cells after viral infection. Acyclovir
was also used as a drug control in anti-HSV study. At the
maximum non-cytotoxic concentrations of all compounds, the
anti HSV-1 and HSV-2 activities with post-treatment showed
100% inhibition of plaque formation whereas pre-treatment
showed less than 50% inhibition of plaque formation
(Figure 4). The result indicated that chloroform extract, extracted100
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Figure 3. Determination of CC50 of chloroform crude extract, extracted
and puriﬁed MGDG and DGDG from C. nutans on Vero cells.and puriﬁed MGDG and DGDG from C. nutans, standard
MGDG and standard DGDG predominantly affected anti HSV-1
activities in post viral infection with IC50 value of 115.00, 36.00,
40.00, 31.00 and 33.60 mg/mL, respectively and anti HSV-2
activities with IC50 value of 140.00, 41.00, 43.20, 33.40 and
36.80 mg/mL, respectively. In addition, acyclovir expressed the
IC50 value on post-treatment at 0.64 and 0.80 mg/mL for HSV-1
and HSV-2 (Table 1). In particular, extracted and puriﬁed
MGDG and DGDG from C. nutans showed antiviral activity
with selectivity indexes (CC50/IC50) on HSV-1 of 26.0 and 23.1
and on HSV-2 of 23.3 and 21.3, respectively (Table 2).Table 1
Cytotoxicity, anti-HSV activity on post-treatment, and selectivity index
of chloroform crude extract, extracted and puriﬁed MGDG and DGDG
from C. nutans, standard MGDG, standard DGDG and acyclovir.
Compound Cytotoxicity
(CC50, mg/mL)
Anti-HSV activity
(IC50, mg/mL)
HSV-1 HSV-2
Chloroform
crude extract
523.00 ± 4.00 115.00 ± 4.00 140.00 ± 3.00
MGDG from
C. nutans
955.00 ± 7.00 36.00 ± 5.00 41.00 ± 1.00
DGDG from
C. nutans
922.00 ± 4.00 40.00 ± 3.00 43.20 ± 0.40
Standard MGDG ND 31.00 ± 2.00 33.40 ± 0.40
Standard DGDG ND 33.60 ± 0.20 36.80 ± 0.90
Acyclovir ND 0.64 ± 0.07 0.80 ± 0.04
ND: No detection.
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Figure 4. Mode of inhibitory activities of chloroform crude extract, extracted and puriﬁed MGDG and DGDG from C. nutans against HSV-1 (A) and HSV-
2 (B) during different stages of the viral infection.
Viruses were treated with the maximal subtoxic concentration of the compounds. Acyclovir was used as a control in each experiment. Data represented the
percentage of virus inhibition when compared to untreated controls as mean ± SD.
Table 2
Selectivity index of crude extract, extracted and puriﬁed MGDG and
DGDG from C. nutans on the replication of HSV-1 and HSV-2 on post-
treatment.
Compound Selectivity index (CC50/IC50)
HSV-1 HSV-2
Chloroform crude extract 5.0 ± 2.0 4.0 ± 2.0
MGDG from C. nutans 26.0 ± 1.0 23.3 ± 0.9
DGDG from C. nutans 23.1 ± 0.3 21.3 ± 0.3
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For many generations, medicinal plants have been used by
indigenous people for the treatment of many infectious diseases
including HSV infection. Modern medicine currently uses
acyclovir and other nucleoside derivatives have been used in the
treatment of HSV infections. However, these are expensive and
a large number of people, especially from developing countries,
may not be able to afford those expensive drugs. Thus, some
medicinal plants which can be found locally would be an
alternative treatment.
In this study, the antiviral activity of chloroform crude
extract, extracted and puriﬁed MGDG and DGDG from
C. nutans were investigated for their antiviral activity against
HSV-1 and HSV-2 on Vero cells. Cytotoxicity assay is an
important part for evaluation of a potential antiviral agent
because an extract or compounds should be selective for virus
speciﬁc processes with little or no effects on host cellular
metabolism.
Pre-treatment of Vero cells with chloroform extract, extrac-
ted and puriﬁed MGDG and DGDG for 24 h before viral
infection demonstrated that these samples showed 50% pro-
tective effect against the HSV-1 and HSV-2 infection process.
In contrast, the results showed that extracted and puriﬁed
MGDG and DGDG from C. nutans demonstrated 100% inhi-
bition of HSV-1 and HSV-2 replication at the post-infection
step at subtoxic concentration levels. Moreover, extracted and
puriﬁed MGDG and DGDG from C. nutans exhibited anti-HSV
activity at the same level as the standard MGDG and DGDGsamples. The extracted and puriﬁed compounds displayed
moderate anti HSV-1 and HSV-2 activity with IC50 values
ranging from 36.00 to 43.20 mg/mL. In addition, the chloroform
crude extract of C. nutans has shown less effective against
HSV-1 and HSV-2 than the extracted and puriﬁed MGDG and
DGDG. It may postulate that MGDG and DGDG are one of the
main contributors towards the inhibition of herpes virus repli-
cation. The selectivity index shows that extracted and puriﬁed
MGDG and DGDG from C. nutans are selective for the inhi-
bition of HSV-1 and HSV-2 infection. Similar to the acyclovir,
extracted and puriﬁed MGDG and DGDG inhibit HSV-1 and
HSV-2 replication. Acyclovir speciﬁcally inhibits the viral
DNA polymerase during the replication cycle when new viral
DNA is synthesized [26]. From this study, it could be said that
the inhibitory activities against HSV-1 and HSV-2 of extracted
and puriﬁed MGDG and DGDG from C. nutans are the most
effective in the post step of infection. Even though the mech-
anism of anti-HSV activity of MGDG and DGDG is still not
clear, a report showed that some monoglycerides showed anti-
viral activities against enveloped viruses by the destruction of
viral envelopes [27].
Study of the synthetic monoglycosyl diglycerides also
showed inhibitory activity against HSV-1 and HSV-2 in Vero
cells [19]. This is in accordance with previous study that reported
the inhibitory effect of C. nutans extract against HSV-1 and
HSV-2 infection before viral entry to the host cells [15]. The
active constituent from C. nutans, chlorophyll a and
chlorophyll b, were also found to have anti-HSV activity
before viral entry step [16]. Other investigators have also reported
anti-HSV activities of hexane, dichloromethane and methanol
extracts from C. nutans at the post step of infection [15]. It is
interesting to note that this differs to a study where water and
organic solvent extracts of C. nutans did not inhibit HSV
replication in Vero cells [28,29].
In conclusion, this study has discovered the inhibitory ac-
tivities of extracted and puriﬁed MGDG and DGDG from
C. nutans against HSV-1 and HSV-2 probably in post viral entry
step. C. nutans is a Thai herbal medicine used for herpes
infection for many generations and the herb is generously
available throughout Southeast Asia. MGDG and DGDG from
C. nutans have been demonstrated to have anti-herpes simplex
Sirada Pongmuangmul et al./Asian Pac J Trop Biomed 2016; 6(3): 192–197 197activity at the same level as commercially available synthetic
compounds.
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